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Abstract Conventional methods to measure ligand-receptor
binding parameters typically require radiolabeled ligands as
probes. Despite the robustness of radioligand binding assays,
they carry inherent disadvantages in terms of safety precau-
tions, expensive synthesis, special lab requirements, and waste
disposal. Mass spectrometry (MS) is a method that can selec-
tively detect ligands without the need of a label. The sensitiv-
ity of MS equipment increases progressively, and currently, it
is possible to detect low ligand quantities that are usually
found in ligand binding assays. We developed a label-free
MS ligand binding (MS binding) assay on the adenosine A1
and A2A receptors (A1AR and A2AAR), which are well-
characterized members of the class A G protein-coupled re-
ceptor (GPCR) family. Radioligand binding assays for both
receptors are well established, and ample data is available to
compare and evaluate the performance of an MS binding as-
say. 1,3-Dipropyl-8-cyclopentyl-xanthine (DPCPX) and
4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-[1,3,
5]triazin-5-yl)amino)ethyl)phenol (ZM-241,385) are high-
affinity ligands selective for the A1AR and A2AAR, respec-
tively. To proof the feasibility ofMS binding on the A1AR and
A2AAR, we first developed an MS detection method for un-
labeled DPCPX and ZM-241,385. To serve as internal stan-
dards, both compounds were also deuterium-labeled.
Subsequently, we investigated whether the two unlabeled
compounds could substitute for their radiolabeled counter-
parts as marker ligands in binding experiments, including sat-
uration, displacement, dissociation, and competition associa-
tion assays. Furthermore, we investigated the accuracy of
these assays if the use of internal standards was excluded.
The results demonstrate the feasibility of the MS binding as-
say, even in the absence of a deuterium-labeled internal stan-
dard, and provide great promise for the further development of
label-free assays based on MS for other GPCRs.
Keywords MSbinding .Mass spectrometry . Radioligand
binding . Adenosine receptor . Deuteration
Introduction
Conventional methods to measure ligand-receptor binding pa-
rameters typically require labeled probes such as radiolabeled
[1] or fluorescently labeled ligands [2]. Despite the robustness
of radioligand binding assays, they carry inherent disadvan-
tages in terms of safety precautions, expensive synthesis, spe-
cial lab requirements, and waste disposal. Alternatively, the
addition of fluorescent moieties holds a substantial risk of
affecting the pharmacological properties of a ligand; more-
over, in many instances, it is also required to engineer the
receptor protein, in particular for fluorescence resonance en-
ergy transfer assays [3].
The development of the mass spectrometry (MS) binding
assay by the group of Wanner permits to measure binding of
an unlabeled ligand to its target [4]. Instead of the radiolabeled
ligand in radioligand binding assays, an unlabeled marker
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ligand is employed in MS binding assays. The amount of
marker ligand bound to the target receptor is detected by mass
spectrometry. As the mass of the molecule itself is detected, a
label is not necessary. However, the marker ligand still has to
fulfill the same requirements as radioligands: high affinity and
selectivity for the target and low non-specific binding [5].
Therefore, it is practical to choose a ligand for MS binding
applications that has already been validated as a good
radioligand. This also ensures a straightforward validation of
an MS binding assay by comparing it to existing radioligand
binding assays.
In this study, we developed an MS binding assay for the
adenosine A1 (hA1AR) and adenosine A2A receptors
(hA2AAR). The particular robustness and abundance of pub-
lished results of radioligand binding assays on the hA1AR and
hA2AAR make these receptors good candidates for develop-
ment of an MS binding assay [6]. The adenosine receptors are
members of the class A of G protein-coupled receptors
(GPCRs). Both receptors are important in physiology. The
hA1AR has been related to sleep regulation, epilepsy, and
asthma. The hA2AAR is implicated in neurodegeneration, in-
flammatory diseases, and cancer pathogenesis. Both receptors
are involved in cardiovascular physiology [6, 7]. As marker
ligands for the MS binding assay, we chose 1,3-dipropyl-8-
cyclopentyl-xanthine (DPCPX) for the hA1AR and 4-(2-((7-
amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-[1,3,5]triazin-5-
yl)amino)ethyl)phenol (ZM-241,385) for the hA2AAR. These
ligands are well-established radioligands for their respective
targets and hence a logical choice to serve as marker ligands in
MS binding assays [8, 9].
The development of liquid chromatography-MS (LC-
MS) detection methods for non-labeled DPCPX and ZM-
241,385 as marker ligands involved the following steps.
Firstly, deuterated isotopologues of the marker ligands were
synthesized to serve as internal standards for increased ac-
curacy of the MS detection. In MS detection methods, it is
common to add a fixed amount of an internal standard to
each sample to compensate for ion suppression, sample
evaporation, and instrumental drift [10]. Technically, the
use of deuterium-labeled internal standards makes the MS
binding assay a labeled assay, even if the marker ligand that
binds to the target is unlabeled itself. Therefore, we also
investigated whether the results of the MS binding assays
were accurate in the absence of an internal standard.
Secondly, a fast LC method was developed to separate the
marker ligands from cell membrane contents in the sample.
The duration of the LC separation is the limiting step for the
throughput of the method so this is preferably fast, i.e.,
within 1 min. Thirdly, for MS detection, a triple quadrupole
MS (TQMS) was employed, which has the required sensi-
tivity to measure typical bound ligand quantities of ligand
binding assays, in the pM range. In a TQMS, the parent ions
with the mass of the molecule of interest are filtered by the
first quadrupole, which are then fragmented in the second
quadrupole. The fragmentation results in daughter ions that
are analyzed by the third quadrupole. This setup ensures a
high selectivity and sensitivity for the detection of a mole-
cule of interest [11].
After establishing the LC-MS methods for detection of
the marker ligands, the MS binding assays were performed
with and without deuterium-labeled internal standard, and
analogous to radioligand binding assays. Saturation, asso-
ciation, and dissociation assays were performed to deter-
mine the affinity and kinetic rates of the marker ligands
DPCPX for the hA1AR and ZM-241,385 for the hA2AAR.
Then displacement and competition association assays were
performed to determine the affinity and kinetic rates of li-
gands competing with the marker ligands. The ensuing re-
sults were compared to and validated with reference
radioligand binding data.
Materials and methods
Materials
Adenosine deaminase (ADA) was purchased from
Boehringer Mannheim (Mannheim, Germany). DPCPX,
5′-N-ethylcarboxamidoadenosine (NECA), and bovine se-
rum albumin (BSA) were purchased from Sigma (St. Louis,
MO, USA). ZM-241,385 was purchased from Ascent
Scientific (Bristol, UK). N6-Cyclopentyladenosine (CPA)
was purchased from Abcam Biochemicals (Cambridge,
UK). 6-(2,2-Diphenylethylamino)-9-((2R,3R,4S,5S)-
5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-
N-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9H-
purine-2-carboxamide (UK-432,097) was obtained as a gift
through Pfizer’s Compound Transfer Program. 3-(3-
Hyd r o x y p r o p y l ) - 7 -m e t h y l - 1 - p r o p a r g y l - 8 - (m -
methoxystryryl)xanthine (MSX-2) [12] was a gift from
Prof. C. E. Müller (Bonn University, Germany). 8-
Cyclopentyltheophylline (8-CPT) was purchased from
Research Biochemicals Inc. (Natick, MA, USA). 8-
Cyclopentyl-3-(3-((4-(fluorosulfonylbenzoyl)oxy)propyl)-
1-propylxanthine (FSCPX) [13] and N5-(2-(4-(2,4-
difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,
4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (LUF6632)
[14] were synthesized in-house. Bicinchoninic acid (BCA)
and BCA protein assay reagent were obtained from Pierce
Chemical Company (Rockford, IL, USA). CHO cells stably
expressing the hA1AR (CHO-hA1AR) were a gift from
Prof. S. Hill (University of Nottingham, UK). HEK293 cells
stably expressing the hA2AAR (HEK293-hA2AAR) were a
gift from Dr. J. Wang (Biogen/IDEC, Cambridge, MA,
USA). All other chemicals were of analytical grade and
obtained from standard commercial sources.
582 Purinergic Signalling (2015) 11:581–594
General synthesis procedures
Demineralised water is simply referred to as H2O, as was used
in all cases unless stated otherwise. 1H and 13C NMR spectra
were recorded on a Bruker AV 400 liquid spectrometer (1H
NMR, 400 MHz; 13C NMR, 100 MHz) at ambient tempera-
ture. Chemical shifts are reported in parts per million (ppm),
are designated by δ, and are downfield to the internal standard
tetramethylsilane (TMS) in CDCl3. Coupling constants are
reported in Hertz and are designated as J. Analytical purity
of the final compounds was determined by high pressure liq-
uid chromatography (HPLC) with a Phenomenex Gemini
3-μm C18 110A column (50×4.6 mm, 3 μm), measuring
UV absorbance at 254 nm. Sample preparation and HPLC
method were—unless stated otherwise—as follows: 0.3–
0.8 mg of compound was dissolved in 1 ml of a 1:1:1 mixture
of CH3CN/H2O/tBuOH and eluted from the column within
15 min, with a three-component system of H2O/CH3CN/1 %
TFA inH2O, decreasing polarity of the solvent mixture in time
from 80:10:10 to 0:90:10. All compounds showed a single
peak at the designated retention time and were at least 95 %
pure. The synthesized compounds were identified by LC-MS
analysis using a Thermo Finnigan Surveyor-LCQ Advantage
Max LC-MS system and a Gemini C18 Phenomenex column
(50×4.6 mm, 3 μm). The sample preparation was the same as
for HPLC analysis. The elution method was set up as follows:
1–4 min isocratic system of H2O/CH3CN/1 % TFA in H2O,
80:10:10, from the fourth minute, a gradient was applied from
80:10:10 to 0:90:10 within 9 min, followed by 1 min of equil-
ibration at 0:90:10 and 1 min at 80:10:10. Thin-layer chroma-
tography (TLC) was routinely performed to monitor the prog-
ress of reactions, using aluminum-coated Merck silica gel
F254 plates. Purification by column chromatography was
achieved by use of Grace Davison Davisil silica column ma-
terial (LC60A 30–200 μm). Solutions were concentrated
using a Heidolph laborota W8 2000 efficient rotary evapora-
tion apparatus and by a high vacuum on a Binder APT line
Vacuum Drying Oven.
Preparation of 8-cyclopentyl-1,3-bis(propyl-2,3-d2)-
3,9-dihydro-1H-purine-2,6-dione 2 ([2H4]DPCPX)
Synthesis steps to arrive to compound 1 (SI Scheme 3) were
performed as previously described [15–17]. 1,3-Diallyl-8-
cyclopentyl-3,9-dihydro-1H-purine-2,6-dione 1 (1 mmol,
300 mg) and NaBD4 (4 mmol, 167 mg) were placed in a flask.
The flask was flame-dried under vacuum to remove traces of
water and then purged with N2 gas. Dry THF (10 ml) was
added. RhCl(PPh3)3 was placed in another flame-dried flask
under N2-atmosphere and suspended in dry THF (1 ml). The
flask containing 1 was heated to 60 °C, and the reaction was
started upon addition of the catalyst suspension, followed by
D2O (2 mmol, 0.04 ml). The mixture was stirred at 60 °C for
19 h. The reaction mixture was then poured into EtOAc and
washed with brine (3×). The organic layer was dried over
MgSO4 and concentrated. The crude product was purified
by column chromatography (PET/EtOAc 5/1→4/1→3/2).
The product 2 was obtained as white solid (46 %, 0.46 mmol,
141 mg). 1H NMR (400 MHz, CDCl3): δ 11.92 (br s, 1H),
4.11–4.06 (m, 2H), 4.03–3.97 (m, 2H), 3.30–3.21 (m, 1H),
2.18–2.11 (m, 2H), 1.98–1.68 (m, 8H), 0.99–0.94 (m, 4H)
ppm. MS: [M+H]+ calculated 309.22, found 309.20. HPLC
purity 97 % (tR 9.587 min, mobile phase 15–65 %
MeCN/H2O+TFA).
Preparation of 4-(2-((7-amino-2-(furan-2-yl)-
1,3a-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)
amino)ethyl)phen-2,3,5,6-d4-ol 5 ([
2H4]ZM-241,385)
Synthesis steps to arrive to compounds 3 and 4 (SI Scheme 4)
were performed as previously described [18–20].
[2H4]Tyramine 4 (0.37 mmol, 53 mg) was suspended in
4 ml MeCN, and Et3N (0.14 ml) and 2-(furan-2-yl)-
5-(methylsulfonyl)-1,3a-dihydro-[1,2,4]triazolo[1,5-a][1,3,
5]triazin-7-amine 3 (0.34 mmol, 95 mg) were added. The
mixture was stirred for 3 h at 70 °C under microwave irradi-
ation. The solvent was evaporated, and the crude material was
adsorbed onto silica and purified by column chromatography
(EtOAc/MeOH 99/1) and subsequent PTLC (EtOAc/MeOH
99.5/0.5) to give the product 5 as an off-white solid (45 %,
0.15 mmol, 52 mg). 1H NMR (400 MHz, DMSO-d6): δ 9.17
(s, 1H), 8.13 (br s, 2H), 7.86 (s, 1H), 7.53–7.52 and 7.50–7.42
(m, 1H, rotamers), 7.05 (d, J=3.2, 1H), 6.67 (m, 1H), 3.43–
3.40 (m, 2H), 2.74–2.71 (m, 2H) ppm. MS: [M+H]+ calculat-
ed 342.16, found 342.7. HPLC purity 95 % (tR 6.408 min,
mobile phase 10–90 % MeCN/H2O+TFA).
Cell culture
CHO-hA1AR cells were grown in Ham’s F12 medium con-
taining 10 % normal adult bovine serum, 100 μg/ml strepto-
mycin, 100 IU/ml penicillin, and 400 μg/ml G418, at 37 °C in
5 % CO2. HEK293-hA2AAR cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10 %
newborn calf serum, 50 μg/ml streptomycin, 50 IU/ml peni-
cillin, and 200 μg/ml G418, at 37 °C and 7 % CO2. Cells were
subcultured twice a week on 10-cm ø plates at a ratio of 1:20
for CHO hA1R cells and 1:8 for HEK293 hA2AAR cells.
Membrane preparation
CHO-hA1AR and HEK293-hA2AAR cells were grown as de-
scribed above. Membranes were prepared as follows. Cells
were detached from plates grown to confluency by scraping
them into 5 ml PBS, collected and centrifuged at 700g
(3000 rpm) for 5 min. Pellets derived from 20 plates (10 cm
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ø) were pooled and resuspended in 16 ml of ice-cold assay
buffer (50 mM Tris-HCl, 5 mM MgCl2, pH 7.4). An Ultra-
Turrax was used to homogenize the cell suspension.
Membranes and the cytosolic fraction were separated by cen-
trifugation at 100,000g (31,000 rpm) in a Beckman Optima
LE-80K ultracentrifuge at 4 °C for 20 min. The pellet was
resuspended in 8 ml of Tris buffer and the homogenization
and centrifugation step was repeated. Assay buffer (4 ml) was
used to resuspend the pellet, and adenosine deaminase (ADA)
was added (0.8 IU/ml) to break down endogenous adenosine.
Membranes were stored in 250-μl aliquots at −80 °C.
Membrane protein concentrations were measured using the
BCA (bicinchoninic acid) method [21].
Radioligand binding assays
The reference radioligand binding data were published before
by our lab or were acquired as described before [22, 23].
Membrane harvesting procedure MS binding assays
One hundred-microliter membrane aliquots containing 5 μg
(CHO-hA1AR) or 22 μg (HEK293-hA2AAR) of protein in
assay buffer were harvested by rapid vacuum filtration
through 1-μm glass fiber AcroPrep Advance 96 filter plates
(Pall Corporation, Ann Arbor, MI, USA) using an extraction
plate manifold (Waters, Milford, MA, USA) and a 12-channel
electronic pipette (Gilson, Middleton, WI, USA). Filters were
subsequently washed three times with ice-cold assay buffer
and dried for 1 h at 55 °C. It was essential that the filter plates
were completely dry before continuing with ligand elution as
described below in BSample elution.^
MS binding saturation assays
Membrane aliquots containing 5 μg (CHO-hA1AR) or 22 μg
(HEK293-hA2AAR) of protein were incubated in a total vol-
ume of 100 μl of assay buffer at 25 °C for 1 h (hA1AR) or at
4 °C for 3 h (hA2AAR). Total binding was determined at
increasing concentrations of marker ligand DPCPX (0.08–
40 nM on hA1AR) or marker ligand ZM-241,385 (0.05–
15 nM on hA2AAR). Dilutions were prepared with a HP
D300 Digital Dispenser (Tecan Group, Männerdorf, Swiss)
from DMSO stocks. Non-specific binding in presence of
100 μM CPA (hA1AR) or 100 μM NECA (hA2AAR) was
determined at three concentrations of marker ligand and ana-
lyzed by linear regression. Incubations were terminated and
samples were harvested as described under BMembrane har-
vesting procedure MS binding assays.^
MS binding displacement assays
Ligand displacement experiments were performed using nine
concentrations of competing ligand. For the hA1AR, the com-
peting ligands used were CPA, 8-CPT, ZM-241,385, and
NECA, while for the hA2AAR, they were UK-432,097,
MSX-2, DPCPX, and NECA. As marker ligand DPCPX
was used for the hA1AR at a concentration of 6 nM, and
ZM-241,385 for the hA2AAR at a concentration of 3 nM.
Non-specific binding was determined in the presence of
Scheme 1 Synthesis of
[2H4]DPCPX (2). Reagents and
conditions: Rh(PPh3)3Cl, NaBD4,
D2O, dry THF, 60 °C, 3.5 h
Table 1 Mass of detected parent and daughter ions. Parent ions were
fragmented to daughter ions with different optimal collision energies for
each daughter ion
Parent ion Daughter ion Collision energy (V)
DPCPX 305.00 178.15 35
204.10 36
221.15 27
263.10 23
[2H]DPCPX 309.00 178.10 36
204.05 35
221.05 29
265.00 23
ZM-241,385 338.10 77.05 55
121.05 29
176.10 30
218.10 24
[2H]ZM-241,385 342.10 80.05 65
125.10 30
176.05 32
218.05 26
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100 μM CPA for the hA1AR and 100 μM NECA for the
hA2AAR. Incubations were terminated as described under
BMembrane harvesting procedure MS binding assays.^
MS binding association assays
Membrane aliquots containing 5 μg/100 μl (CHO-hA1AR) or
22 μg/100 μl (HEK293-hA2AAR) of protein were incubated in
a total volume of 2400 μl of assay buffer at 25 °C with 6 nM
DPCPX for hA1AR or at 4 °C with 3 nM ZM-241,385 for
hA2AAR. At each time point, 100 μl from the reaction mix
was harvested as described under BMembrane harvesting pro-
cedure MS binding assays^ to determine the amount of marker
ligand bound to the receptor. Non-specific binding was deter-
mined as described under BMS binding displacement assays.^
MS binding dissociation assays
Membrane aliquots containing 5 μg/100 μl (CHO-hA1AR) or
22 μg/100 μl (HEK293-hA2AAR) of protein were incubated
in a total volume of 2400μl of assay buffer at 25 °Cwith 6 nM
DPCPX (hA1AR) or at 4 °C with 3 nM ZM-241,385
(hA2AAR). The reaction mixes were allowed to reach equilib-
rium for 1 h before starting the dissociation by adding 100 μM
CPA (hA1AR) or NECA (hA2AAR). At each time point,
100μl from the reactionmix was harvested as described under
BMembrane harvesting procedure MS binding assays^ to de-
termine the amount of marker ligand still bound to the recep-
tor. Non-specific binding was determined as described under
BMS binding displacement assays.^
MS binding competition association assays
Membrane aliquots containing 5 μg/100 μl (CHO-hA1AR) or
22 μg/100 μl (HEK293-hA2AAR) of protein were incubated
in a total volume of 2400μl of assay buffer at 25 °Cwith 6 nM
DPCPX in the absence or presence of 250 nM 8-CPT or
250 nM FSCPX (hA1AR) or at 4 °C with 3 nM ZM-241,
385 in the absence or presence of 90 nM MSX-2 or 15 nM
LUF6632 (hA2AAR). At each time point, 100 μl from the
reaction mix was harvested as described under BMembrane
harvesting procedure MS binding assays^ to determine the
amount of marker ligand bound to the receptor. Non-specific
binding was determined as described under BMS binding dis-
placement assays.^
Sample elution
The ligand was eluted from the ligand-receptor complex on
the dried filter plates over which MS binding samples were
Fig. 1 Standard curve of increasing concentrations of marker ligands a
DPCPX with 2 nM [2H]DPCPX and b ZM-241,385 with 2 nM [2H]ZM-
241,385 in matrix membrane samples. On the x-axis is plotted the
concentration of marker ligand. On the y-axis is plotted the marker area
TIC divided by IS area TIC (M/IS). Data shown is the average of M/IS
values±SEM from four runs in hexaplicate
Scheme 2 Synthesis of
[2H4]ZM-241,385 (5). Reagents
and conditions: Et3N, MeCN,
MW, 70 °C, 3 h
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harvested. One hundred microliters of eluent (50 % metha-
nol, 50 % ammonium formate buffer [final concentration
5 mM] at pH 7, spiked with 2 nM [2H]DPCPX or
[2H]ZM-241,385 as internal standard, all HPLC grade)
was applied to the filter plates which were then centrifuged
for 1 min at 800g (2000 rpm) in a 5810 plate centrifuge
(Eppendorf, Hamburg, Germany), while filter eluates were
collected in 1.1-ml polystyrene deep 96-well plates
(BrandTech Scientific, Essex, CT, USA). This procedure
was performed twice resulting in a total of 200 μl eluate
for each sample. For standard curve samples, the same pro-
cedure was followed but for the presence of increasing con-
centrations (1–100 pM) of DPCPX or ZM-241,385 in the
eluent. After elution, 96-deep-well plates were sealed with
rapid easy pierce film (Nacalai, San Diego, CA, USA) and
stored at −20 °C before LC-MS-MS quantification.
Fig. 2 Typical chromatograms of
a non-specific binding of DPCPX
(31 pM), b total binding of
DPCPX (242 pM), and c
[2H]DPCPX (2 nM) in eluate
containing hA1AR membrane
matrix, and of d non-specific
binding of ZM-241,385 (42 pM),
e total binding of ZM-241,385
(289 pM), and f [2H]ZM-241,385
(2 nM) in eluate containing
hA2AAR membrane matrix. The
red lines delineate the area of
peak integration
586 Purinergic Signalling (2015) 11:581–594
LC-MS-MS quantification
All solvents used were of LC-MS grade or better. The
LC-ESI-MS-MS setup consisted of a Nexera X2
UHPLC (Shimadzu, Kyoto, Japan; degassing unit:
20A3R, autosampler: 30AC, column oven: 30AD) and
a LCM-8050 triple quadrupole mass spectrometer
(Shimadzu, Kyoto, Japan) with an electrospray ioniza-
tion source (ESI) in positive mode. Chromatographic
separation was performed on an Acquity UPLC BEH
C18 column (1×50 mm, 1.7 μm; Waters, Milford,
MA, USA) with a VanGuard precolumn of the same
type (2.1×5 mm). The column oven was set at 40 °C.
Mobile phases consisted of acetonitrile, methanol, and
ammonium formate buffer (final concentration 5 mM)
at pH 7, all of LC-MS grade or better, in respective
volume fractions of 5:5:90 (solvent A) and 45:45:10
(solvent B). An isocratic mobile phase flow of 0.2 ml/
min was applied consisting of solvents A:B (10:90 for
the DPCPX and 35:65 for the ZM-241,385 quantifica-
tion methods), which resulted in column pressures of
400 and 500 bar, respectively. The sample eluate injec-
tion volume was 20 μl and run time was 1 min. Source
and fragmentation parameters were acquired by the
Shimadzu optimization for method function (Table 1).
For each ligand, the parent and four daughter ions were
detected by multiple reaction monitoring (MRM) in pos-
itive mode. Additional MS settings were as follows: ESI
interface temperature 300 °C; DL temperature 250 °C;
heat block temperature 400 °C; ion spray voltage 4 kV;
heating and drying gas flows 10 l/min; nebulizing gas
flow 3 l/min.
Data analysis
Shimadzu LabSolutions software (Shimadzu, Kyoto,
Japan) was used to analyze resulting chromatogram peaks.
The peak area of the total ion count (TIC) of the daughter
ions was calculated at the expected retention times,
resulting in marker and internal standard peak area. To
compensate for eluent evaporation and signal suppression
by matrix effects from the membrane sample, marker peak
area was divided by internal standard peak area (M/IS).
Lower limit of quantitation (LLOQ) values of each mark-
er ligand were defined as the lowest concentration in
membrane matrix where signal to noise ratio was higher
than 5, the standard deviation within and between runs in
hexaplicate was lower than 20 % (and for all higher con-
centrations lower than 15 %), and calculation of concen-
tration by a function derived from 1/x2 linear regression
deviated from nominal values less than 20 %. M/IS values
were converted to concentration of marker ligand in pM
using the function established by 1/x2 linear regression on
the 10–100-pM standard curve results. The resulting MS
binding data was then analyzed with GraphPad Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA). Marker
ligand displacement curves were fitted to one- and two-
state site binding models. kon and koff values of the marker
ligands DPCPX and ZM-241,385 were derived by fitting
one-phase associat ion and dissociat ion models .
Association and dissociation rates for the competing li-
gands were calculated by fitting the data to the competi-
tion association model using Bkinetics of competitive
binding^ [24]. Log-transformed Ki, KD, kon, and koff
values from MS binding and radioligand binding assays
Fig. 3 Saturation of DPCPX
binding to hA1AR (a, b) and ZM-
241,385 binding to hA2AAR (c,
d). Increasing concentrations of
marker ligands were incubated
with the respective membranes.
Data shown without (a, c) and
with (b, d) non-specific binding
values subtracted. Graphs show
mean values of one representative
MS binding saturation
experiment performed in
duplicate
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were plotted, and a linear regression analysis was applied.
A similar correlation plot was prepared with values from
MS binding assays based on solely marker peak area
values instead of M/IS.
Results
Synthesis of [2H4]DPCPX 2
[2H4]DPCPX 2 was prepared according to the synthetic route
shown in Scheme 1 and SI Scheme 3 and was adopted from
previously described syntheses of non-deuterated DPCPX
[15–17]. After the synthesis steps to arrive at compound 1
(SI Scheme 3), the allylic double bonds of the DPCPX pre-
cursor 1 were reductively deuterated in the presence of
Wilkinson’s catalyst with NaBD4 as a deuterium source gen-
erating deuterium gas in situ upon addition of D2O [25]. The
mass spectrum showed a mass range for the (M+H+) species
from 305.20 ([2H0] isotopologue) to 313.27 ([
2H8]
isotopologue) in a Gaussian distribution with the desired
[2H4]DPCPX 2 as most abundant isotopologue generating
the main mass peak at 309.33.
Synthesis of [2H4]ZM-241,385 5
[2H4]ZM-241,385 5 was prepared according to the synthetic
route shown in Scheme 2 and SI Scheme 4 and was adopted
from previously described syntheses of non-deuterated ZM-
241,385 [18–20]. After the synthesis steps to arrive at com-
pounds 3 and 4 (SI Scheme 4), reaction of the [2H4]tyramine 4
with methylsulfone compound 3 yielded the final product
[2H4]ZM-241,385 5 [18]. MS analysis showed a mass of
342.7 (M+H+) and confirmed the incorporation of four deu-
terium atoms in the final product.
Fig. 5 Association (a, c) and
dissociation (b, d) of DPCPX on
hA1AR (a, b) and ZM-241,385
on hA2AAR (c, d). Graphs show
mean values of one representative
MS binding association or
dissociation experiment
performed in duplicate
Fig. 4 Displacement of DPCPX binding to hA1AR byCPA, 8-CPT, ZM-
241,385, or NECA (a) and of ZM-241,385 binding to hA2AAR by UK-
432,097, MSX-2, DPCPX, or NECA (b). Non-specific binding is plotted
at −3 on the x-axis. Graphs show mean values of one representative MS
binding displacement experiment performed in duplicate
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LC-MS results of DPCPX, [2H]DPCPX, ZM-241,385,
and [2H]ZM-241,385
Standard curves were made for the quantitation of DPCPX
and ZM-241,385 concentrations in biological membrane ma-
trix by LC-MS (Fig. 1). Membrane samples without addition
of ligand were filtered, and the applied eluent contained in-
creasing concentrations of DPCPX and ZM-241,385, in addi-
tion to 2 nM of their deuterated counterparts. This method
ensured standard curves in presence of the same biological
matrix as for the quantitated MS binding samples. The
LLOQ values derived from the standard curves were 20 pM
for DPCPX and 40 pM for ZM-241,385 and were below non-
specific binding concentrations found in MS binding assays
for DPCPX (31 pM) and ZM-241,385 (42 pM). The linear
regression equations to calculate marker ligand concentrations
from the M/IS values derived from the standard curves were
y=0.00341x+0.117 with R2=0.988 for DPCPX and y=
0.00130x+0.0225 with R2=0.987 for ZM-241,385.
Binding assays
DPCPX and ZM-241,385 were used as marker ligands for the
MS binding assays. These marker ligands are also available as
well-established tritium-labeled radioligands with high affini-
ty for respectively the hA1AR and hA2AAR, which made it
possible to validate the MS binding assays. For the displace-
ment assays, the competing ligands on the hA1AR were CPA
(selective agonist), 8-CPT (selective antagonist), ZM-241,385
(hA2AAR-selective antagonist), and NECA (non-selective ag-
onist), and on the hA2AAR, they were UK-432,097 (selective
agonist), MSX-2 (selective antagonist), DPCPX (hA1AR-se-
lective antagonist), and NECA. For the competition associa-
tion assays, the competing ligands on the hA1AR were 8-CPT
(fast dissociation) and FSCPX (irreversibly binding to hA1AR
resulting in an apparent slow dissociation), and on the
hA2AAR, they were MSX-2 (fast dissociation) and
LUF6632 (slow dissociation). Marker ligand concentrations
that were found in the eluates of theMS binding assays ranged
from 31 to 242 pM for DPCPX and 42 to 289 pM for ZM-241,
385 (Fig. 2). The MS binding data in Figs. 3, 4, 5, and 6 and
Tables 2, 3, 4, 5, and 6 is based on data with deuterium-labeled
internal standard compensation of the marker ligand peak area
(M/IS), except when stated otherwise in Tables 5 and 6. In
Fig. 7, both M/IS-based and marker peak area-based (without
internal standard compensation and thus completely unla-
beled) data are compared with radioligand binding data.
For the validation of MS binding assays, radioligand bind-
ing data that was published previously by our group was used.
In the case that no in-house radioligand binding data was
available, the concerning assays were performed following
previously established protocols [22, 23]. Radioligand bind-
ing data for the marker ligands DPCPX and ZM-241,385 on
their respective targets from saturation, association, and dis-
sociation assays was published previously (Table 2).
Displacement and competition association radioligand bind-
ing data of the competing ligands NECA (displacement on
hA1AR and hA2AAR), UK-432,097 (displacement on
hA2AAR), FSCPX (competition association on hA1AR), and
LUF6632 (competition association on hA2AAR) was avail-
able as well from previous publications (Tables 3, 4, 5, and
6). Newly acquired radioligand binding data was from
radioligand displacement assays with CPA, 8-CPT, and ZM-
241,385 on the hA1AR; radioligand displacement assays with
MSX-2 and DPCPX on the hA2AAR; and radioligand com-
petition association assays with 8-CPT on the hA1AR and
with MSX-2 on the hA2AAR.
MS binding saturation of the marker ligands DPCPX and
ZM-241,385 to the hA1AR and hA2AAR, respectively, fitted a
one-site saturation binding model (Fig. 3). DPCPX had an
affinity of 3.43±0.02 nM and a Bmax of 17.3±0.3 pmol/mg
protein for the hA1AR which was well in accordance with the
previously found data from radioligand binding assays of 2.5
±0.1 nM and 14±1 pmol/mg protein, respectively (Table 2).
The same was true for ZM-241,385 with an MS binding af-
finity of 1.03±0.07 nM and Bmax of 2.3±0.3 pmol/mg protein
for the hA2AAR, compared to a radioligand binding affinity of
0.60±0.07 nM and Bmax of 1.9±0.4 pmol/mg protein. The
displacement of marker ligands DPCPX and ZM-241,385
binding from the hA1AR and hA2AAR by their competing
ligands fitted well to either one-state or two-state ligand bind-
ing displacement models (Fig. 4). The affinities found in MS
Fig. 6 Competition association of DPCPX on hA1AR in the presence or
absence of 250 nM 8-CPT and 250 nM FSCPX (a), and of ZM-241,385
on hA2AAR in the presence or absence of 90 nM MSX-2 and 15 nM
LUF6632 (b). Graphs show mean values of one representative MS bind-
ing competition association experiment performed in duplicate
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binding displacement assays for the competing ligands CPA,
8-CPT, ZM-241,385, and NECA for the hA1AR (Table 3) and
UK-432,097, MSX-2, DPCPX, and NECA for the hA2AAR
(Table 4) were in good agreement to the radioligand binding
assays. The two-state binding model fits observed for the ag-
onists CPA and NECA on the hA1AR were observed in
radioligand binding assays as well, and the resulting high
and low affinity values were in good agreement (Table 3).
The association and dissociation of marker ligands DPCPX
and ZM-241,385 to the hA1AR and hA2AAR fitted well to
one-phase association and dissociation models (Fig. 5), and
the resulting association and dissociation rates were in good
agreement between MS binding and radioligand binding as-
says (Tables 5 and 6).
With the association and dissociation rates validated for the
marker ligands, MS binding competition association assays
were performed. The competition association curves in the
presence of FSCPX (hA1AR) and LUF6632 (hA2AAR)
yielded an Bovershoot^ shape typical for slowly dissociating
ligands, while in the presence of 8-CPT (hA1AR) and MSX-2
(hA2AAR), the curves were typical for fast-dissociating li-
gands (Fig. 6). FSCPX displaced the marker ligand DPCPX
completely after 120 min. The association rates of 8-CPT and
MSX-2 agreed well between MS binding and radioligand
binding assays, but less so in case of FSCPX and LUF6632
(Tables 5 and 6). The dissociation rates of 8-CPT,MSX-2, and
LUF6632 were in good agreement as well, but not the appar-
ent dissociation rate of FSCPX.
Linear regression performed on the correlation plots of MS
binding data (based on M/IS detection) against radioligand
binding data yielded the following coefficients of determina-
tion and equations: R2=0.985 and y=1.04x−0.199 (Ki and
KD, Fig. 7a), R
2=0.775 and y=0.738x+2.09 (kon, Fig. 7c),
and R2=0.968 and y=1.06x−0.0550 (koff, Fig. 7e). Similar
correlation plots ofMS binding data without IS compensation,
solely based on marker peak area, against radioligand binding
data yielded R2=0.988 and y=1.05x−0.299 (Ki and KD,
Fig. 7b), R2=0.735 and y=0.767x+1.82 (kon, Fig. 7d), and
R2=0.940 and y=1.33x−0.0168 (koff, Fig. 7f).
Discussion
Preparation of internal standards
Including an internal or external standard is a good practice in
mass spectrometry, to compensate for ion suppression by ma-
trix effects from cell contents, sample evaporation, and instru-
mental drift [10]. We used the internal standard method as this
is the most accurate manner to compensate for these sources of
signal distortion and to increase the accuracy of MS methods.
Table 4 Affinity (Ki values) of UK-432,097, MSX-2, DPCPX, and
NECA as determined in MS binding and radioligand binding
displacement assays on hA2AAR. Values are mean Ki in nM±SEM of
at least three independent experiments performed in duplicate
Ki±SEM (nM)
MS binding Radioligand binding
UK-432,097 52±1 22±5 [23]
MSX-2 9.0±0.3 5.7±0.1
DPCPX 550±141 667±77
NECA 100±12 64±1 [23]
Table 3 Affinity (Ki values) of CPA, 8-CPT, ZM-241,385, and NECA
as determined in MS binding and radioligand binding displacement
assays on hA1AR. The displacement curves of CPA and NECA fitted to
a two-state site binding model, which yielded high and low binding af-
finities for the receptor. Values are mean Ki in nM±SEM of at least three
independent experiments performed in duplicate
Ki±SEM (nM)
MS binding Radioligand binding
CPA 139±32 175±13
CPA-high 1.2±0.4 1.0±0.5
CPA-low 256±81 304±23
8-CPT 43±11 31±1
ZM-241,385 619±78 523±13
NECA 616±76 731±94 [22]
NECA-high 4.1±1.4 4±1 [22]
NECA-low 1273±56 731±94 [22]
Table 2 Affinity and Bmax values
of DPCPX for the hA1AR and
ZM-241,385 for the hA2AAR as
determined in MS binding and
radioligand binding saturation
assays. Values are mean KD in
nM±SEM and mean Bmax in
pmol/mg protein±SEM of at least
three independent experiments
performed in duplicate
KD±SEM (nM) Bmax (pmol/mg protein)
MS binding Radioligand binding MS binding Radioligand binding
DPCPX on hA1AR 3.43±0.02 2.5±0.1 [29] 17.3±0.3 14±1 [29]
ZM-241,385 on hA2AAR 1.03±0.07 0.60±0.07 [23] 2.3±0.3 1.9±0.4 [23]
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Preferably, the internal standard is a molecule with the same
chemical properties as the molecule of interest but with a
distinct mass. Hence, deuterated DPCPX (d4) and ZM-241,
385 (d4) were synthesized to serve as internal standard for the
MS binding assays on hA1AR and hA2AAR, respectively. The
resulting mass difference between the parent compounds and
their internal standards ensured minimal signal overlap by
their isotope patterns. For the synthesis of [2H4]ZM-241,385
5, the pure isotopologue [2H4]tyrosine (SI 14) was commer-
cially available as precursor for the [2H4]tyramine 4 building
block. For the synthesis of [2H4]DPCPX 2, the building block
1 was deuterated in-house by a rhodium-catalyzed reduction
of two allylic double bonds in the presence of deuterium gas
generated in situ. During this process, deuterium-hydrogen
scrambling occurred which resulted in a mixture of
isotopologues [2H0]DPCPX to [
2H8]DPCPX in a Gaussian
distribution as a final product. This had no negative influence
on the results of the MS Binding assays, since the masses of
parent ions and fragments of the most abundant isotopologue
[2H4]DPCPX 5 were selected for quantification.
MS binding assays
Affinity, association, and dissociation rates measured directly
for the marker ligands DPCPX on the hA1AR and ZM-241,
385 on the hA2AAR were in good agreement to the values
found in radioligand binding assays (Figs. 3 and 5, Tables 2,
5, and 6). The good performance of theMS binding saturation,
association, and dissociation assays in which solely the mark-
er ligand and no competing ligand was present was a prereq-
uisite to continue with the MS binding displacement and com-
petition association assays.
To demonstrate the MS binding displacement assays, a
combination of selective and non-selective agonists and an-
tagonists were chosen as competing ligands. For the hA1AR,
these ligands were CPA, 8-CPT, ZM-241,385, and NECA,
and for the hA2AAR, they were UK-432,097, MSX-2,
DPCPX, and NECA. The determined affinity values were in
good agreement betweenMS binding and radioligand binding
assays for all these competing ligands (Fig. 4, Tables 3 and 4).
Furthermore, the binding of agonists CPA and NECA to the
hA1AR fitted to a pronounced two-phase displacement curve
as was found before in radioligand binding assays.
Kinetic properties of ligands are of emerging interest and
are thought to be important predictors of clinical performance
[3, 26]. Therefore, we developed and validated MS binding
competition association assays, by which kinetic properties of
competing ligands can be analyzed by measuring the amount
of bound marker ligand at different time points, in the pres-
ence of one concentration of these competing ligands. A fast
Table 6 Association and dissociation rates of ZM-241,385, MSX-2,
and LUF6632 determined in MS binding and radioligand binding
assays on the hA2AAR. MS binding (M/IS) values were obtained by
analysis with compensation by internal standard, just as the MS binding
values in Tables 2, 3, and 4. MS binding (marker) values were obtained
by analysis of marker chromatograms solely, without compensation by
internal standard, and thus label-free. The kinetic values of ZM-241,385
were determined by association and dissociation assays, while the kinetic
values of MSX-2 and LUF6632 were determined by competition associ-
ation assays with 3 nM ZM-241,385 as marker ligand. Values are mean
kon in M
−1 min−1±SEM and mean koff in min
−1 of at least three indepen-
dent experiments performed in duplicate
kon±SEM (M
−1 min-1) koff±SEM (min
−1)
MS binding (M/IS) Radioligand binding MS binding (marker) MS binding (M/IS) Radioligand binding MS binding (marker)
ZM-241,385 9.5±0.7×107 13±6×107 [14] 9.8±2.0×107 0.019±0.002 0.014±0.003 [14] 0.021±0.005
MSX-2 5.4±0.6×106 2.4±0.2×106 9.3±1.3×106 0.027±0.005 0.026±0.004 0.063±0.022
LUF6632 0.7±0.1×107 3.4±0.4×107 [14] 1.8±0.7×107 0.0028±0.0001 0.0031±0.0002 [14] 0.030±0.011
Table 5 Association and dissociation rates of DPCPX, 8-CPT, and
FSCPX determined in MS binding and radioligand binding assays on
the hA1AR. MS binding (M/IS) values were obtained by analysis with
compensation by internal standard, just as the MS binding values in
Tables 2, 3, and 4. MS binding (marker) values were obtained by analysis
of marker chromatograms solely, without compensation by internal
standard, and thus label-free. The kinetic values of DPCPX were deter-
mined by association and dissociation assays, while the kinetic values of
8-CPT and FSCPX were determined by competition association assays
with 6 nMDPCPX as marker ligand. Values are mean kon in M
−1 min−1±
SEM and mean koff in min
−1 of at least three independent experiments
performed in duplicate
kon±SEM (M
−1 min−1) koff±SEM (min
−1)
MS binding (M/IS) Radioligand binding MS binding (marker) MS binding (M/IS) Radioligand binding MS binding (marker)
DPCPX 2.0±0.3×108 1.4±0.2×108 [29] 1.7±0.4×108 0.29±0.02 0.25±0.01 [29] 0.31±0.02
8-CPT 5±2×107 6±2×107 3±2×107 1.4±0.5 1.1±0.3 1.2±0.8
FSCPXa 0.7±0.2×106 3.7±1.0×106 [29] 0.7±0.2×106 0.004±0.002 0.0010±0.0002 [29] 0.006±0.004
aApparent kinetic values were calculated for covalently binding FSCPX
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and a slowly dissociating competing ligand were chosen for
each target. Fast- and slow-dissociating ligands yield distinct
characteristic competition association graphs, without and
with overshoot, respectively. For the hA1AR, the ligands 8-
CPT and FSCPX and for hA2AR, MSX-2 and LUF6632 were
tested. 8-CPT and MSX-2 dissociate fast from their targets.
FSCPX is an irreversibly binding antagonist selective for the
hA1R [13, 27, 28] and thus yields the characteristic overshoot
graph for slowly dissociating ligands [29], with the exception
that it eventually displaces the marker ligand DPCPX
completely (Fig. 6a). LUF6632 was characterized earlier as
a slowly dissociating ligand selective for the hA2AAR [14].
Dissociation rates were in good agreement between the MS
binding and radioligand binding competition association as-
says (Fig. 7e, Tables 5 and 6), with the exception of the ap-
parent dissociation rate of the irreversibly binding FSCPX
(Table 5). Association rates found for the competing ligands
in competition association assays varied more, especially for
the slowly or not at all dissociating ligands FSCPX and
LUF6632 (Fig. 7c, Tables 5 and 6). It has to be noted that as
Fig. 7 Correlation plots of results
obtained by MS binding and
radioligand binding assays on
hA1AR and hA2AAR. Values of
marker ligands DPCPX and ZM-
241,385 were measured directly
on their respective binding targets
hA1AR and hA2AAR by
saturation (a, b), association (c,
d), and dissociation (e, f) assays,
while values of the competing
ligands were measured indirectly
by displacement (a, b) and
competition association assays
(c–f). Affinity values in pKD and
pKi (a, b), association rates in kon
(c, d), and dissociation rates in log
koff (e, f) were compared.
Correlation plots a, c, and e show
MS binding results standardized
with deuterium-labeled internal
standard, while b, d, and f show
truly label-free MS binding
results without internal standard.
Data points represent mean values
of at least three separate
experiments performed in
duplicate. R2 values were
calculated by linear regression
performed on log-transformed
values
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it binds irreversibly to the hA1AR, FSCPX does not actually
dissociate from the target. However, fitting the FSCPX data
into the competition association model still enables the calcu-
lation of apparent association and dissociation rates. Being
apparent values, they may vary between studies which could
be an explanation for the diverging kinetic rates of FSCPX
found in MS binding and radioligand binding assays
(Table 5).
Altogether, these results validate the use of MS binding
assays to determine affinity values and dissociation rates by
saturation, association, dissociation, and competition associa-
tion assays. However, association rate determination was only
accurate by direct measurement on the marker ligands.
Necessity of deuterium-labeled internal standard
As mentioned above, including an internal or external stan-
dard is a good practice in mass spectrometry. We used the
internal standard method as this is the most accurate manner
to compensate for sources of signal distortion. However, the
use of a deuterium-labeled internal standard makes the MS
binding assay a labeled assay, even if the marker ligand that
binds to the target is itself unlabeled. For fast screening of new
marker ligands, the use of an external standard or even no
standard at all would be vastly advantageous, as the whole
assay becomes an unlabeled assay. Moreover, to directly de-
termine association and dissociation rates of non-labeled li-
gands would be an improvement over the use of competition
association assays. Therefore, we compared the performance
of the MS binding assay with and without compensation by
deuterium-labeled internal standard. Although in the latter
case the resulting graphs of each separate experiment were
somewhat less accurate, Ki and KD values could still be deter-
mined without loss of accuracy (Fig. 7b). The koff values in-
directly determined by the competition association assay cor-
related less well with radioligand binding assays, although
retaining a good coefficient of determination (Fig. 7f). The
determination of kon values correlated less well with
radioligand binding assays irrespective of the use of an inter-
nal standard (Fig. 7c, d). In contrast to this, the directly mea-
sured association and dissociation rates of marker ligands
DPCPX and ZM-241,385 were still in good agreement with
radioligand binding experiments (Tables 5 and 6).
Conclusion
We developed and validated MS binding assays for the aden-
osine A1 and A2A receptors. The results from ligand satura-
tion, association, dissociation, and displacement assays were
in good agreement with radioligand binding data. The results
from competition association assays were in good agreement
with radioligand binding data for dissociation rates but less so
for association rates. Furthermore, we investigated the neces-
sity to include deuterium-labeled internal standards in MS
binding assays. Saturation, association, dissociation, and dis-
placement assay results were still in good agreement with
radioligand binding assays when the internal standard was
not included. In competition association assays, the inclusion
of an internal standard was beneficial for good correlation of
dissociation rates with radioligand binding data. However, by
excluding the use of internal standards in MS binding assays,
it would be relatively simple to measure association and dis-
sociation rates of a number of unlabeled ligands directly, with-
out the need for competition association assays. We conclude
that the use of deuterium-labeled internal standards is in this
case unnecessary which makes the MS binding assay a truly
unlabeled ligand binding assay. As this internal standard-free
approach may be applied to other targets than the currently
investigated adenosine A1 and A2A receptors, we foresee the
promising future application of MS binding to directly mea-
sure binding properties by saturation, association, and disso-
ciation assays, without the use of any labeled internal
standards.
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